考虑分子亚型时显微手术肿瘤负荷减容在乳腺癌脑转移患者中的作用:一项双中心体积生存分析
该双中心回顾性分析纳入101例手术治疗的乳腺癌脑转移患者,评估切除程度、全切及术后残留肿瘤体积与总生存和颅内无进展生存的关联。结果示切除程度、全切及残留体积与总生存或颅内无进展生存无显著关联,但在无颅外转移患者中更高切除程度和更低残留体积与更长总生存相关。
要点
- 切除程度、全切及残留体积在全队列中与总生存和颅内无进展生存无显著关联。
- 无颅外转移患者中更高切除程度和更低残留体积与更长总生存相关。
- HER2阳性与更长总生存相关,诊断时颅外转移和症状性病灶与更短总生存和颅内无进展生存相关。
核心结论
- 乳腺癌分子亚型、颅外疾病状态和脑转移相关症状与手术治疗乳腺癌脑转移患者的总生存相关。
- 全队列中广泛切除以最小化残留肿瘤体积未显著影响总生存,但在无颅外转移患者中似乎有益。
研究设计与样本
- 回顾性分析两个瑞士三级脑肿瘤中心手术治疗的乳腺癌脑转移患者。
- 最终分析纳入101例患者。
- 采用Cox比例风险模型评估切除程度、全切达成和术后残留肿瘤体积与总生存和颅内无进展生存的关联。
主要发现
- 多数患者(38%)为HER2-/HR+分子亚型,其次为HER2+/HR+(25%)、HER2-/HR-(21%)和HER2+/HR-(13%)。
- 大多数患者接受术后全身治疗(75%)和放疗(84%)。
- 中位总生存和颅内无进展生存分别为22个月和8个月。
- 手术前颅内肿瘤平均体积为26 cm3,术后降至3 cm3。
- 切除程度、全切达成和残留体积与总生存或颅内无进展生存无显著关联,但在无颅外转移患者中更高切除程度和更低残留体积与更长总生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advancements in metastatic breast cancer (BC) treatment have enhanced overall survival (OS), leading to increased rates of brain metastases (BM). This study analyzes the association between microsurgical tumor reduction and OS in patients with BCBM, considering tumor molecular subtypes and perioperative treatment approaches. METHODS: Retrospective analysis of surgically treated patients with BCBM from two tertiary brain tumor Swiss centers. The association of extent of resection (EOR), gross-total resection (GTR) achievement, and postoperative residual tumor volume (RV) with OS and intracranial progression-free survival (IC-PFS) was evaluated using Cox proportional hazard model. RESULTS: 101 patients were included in the final analysis, most patients (38%) exhibited HER2-/HR + BC molecular subtype, followed by HER2 + /HR + (25%), HER2-/HR- (21%), and HER2 + /HR- subtypes (13%). The majority received postoperative systemic treatment (75%) and radiotherapy (84%). Median OS and intracranial PFS were 22 and 8 months, respectively. The mean pre-surgery intracranial tumor volume was 26 cm3, reduced to 3 cm3 post-surgery. EOR, GTR achievement and RV were not significantly associated with OS or IC-PFS, but higher EOR and lower RV correlated with extended OS in patients without extracranial metastases. HER2-positive tumor status was associated with longer OS, extracranial metastases at BM diagnosis and symptomatic lesions with shorter OS and IC-PFS. CONCLUSIONS: Our study found that BC molecular subtypes, extracranial disease status, and BM-related symptoms were associated with OS in surgically treated patients with BCBM. Additionally, while extensive resection to minimize residual tumor volume did not significantly affect OS across the entire cohort, it appeared beneficial for patients without extracranial metastases.
引用
- Bellomo J, Zeitlberger AM, Padevit L, et al. Role of microsurgical tumor burden reduction in patients with breast cancer brain metastases considering molecular subtypes: a two-center volumetric survival analysis. J Neurooncol. 2024. PMID: 38829577. doi:10.1007/s11060-024-04728-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。